XTL Biopharmaceuticals Ltd. XTLB
- Market cap
- $9.7M
- P/E
- 0.0×
Follow XTLB
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.20 | 7.72 | 5.72 | 4.68 | 2.52 | 10.24 | 3.40 | 3.00 | 3.08 | 2.28 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 34.20 | 18.80 | 15.76 | 11.00 | 13.60 | 26.76 | 12.00 | 6.16 | 19.96 | 10.28 |
High Price
|
|||
| 7 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| 0.00% | 0.00% | — | — | 0.00% | 0.00% | 0.00% | — | 0.67% | — |
Gross Margin
|
|||
| (3) | (1) | 3 | (1) | (3) | 0 | (1) | (2) | 0 | (1) |
EBT
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| (3) | (1) | 3 | (1) | (3) | 0 | (1) | (2) | (1) | (7) |
Net Income
|
|||
| 1 | 0 | — | — | 0 | 0 | 0 | — | 0 | — |
Depreciation
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| (3.60) | (0.68) | 2.40 | (1.20) | (2.30) | 0.32 | (0.99) | (1.32) | (0.80) | (3.11) |
Earnings/Sh
|
|||
| (2.53) | (0.96) | (0.63) | (0.71) | (0.66) | (0.79) | (0.66) | (0.52) | (0.24) | (0.11) |
Cash Flow/Sh
|
|||
| (0.10) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 |
Capex/Sh
|
|||
| (2.62) | (0.96) | (0.63) | (0.71) | (0.66) | (0.79) | (0.66) | (0.52) | (0.25) | (0.11) |
Free CF/Sh
|
|||
| 3.92 | 3.08 | 6.47 | 5.43 | 2.81 | 4.01 | 2.94 | 1.63 | 0.81 | (0.03) |
Book Value/Sh
|
|||
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | 9 |
Shares
|
|||
| — | — | — | — | — | — | — | — | 0.00 | — |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | 5.63 | — |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | 1.93 | — |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | 4.84 | — |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | (2.56) | — |
EV/FCF
|
|||
| (2) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) | (1) |
Op' Cash Flow
|
|||
| 0 | 0 | — | 0 | 0 | — | — | — | 0 | — |
Capex
|
|||
| (2) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) | (1) |
FCF
|
|||
| 2 | 6 | 8 | 7 | 6 | 6 | 4 | 2 | (1) | 0 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Total Debt
|
|||
| (2) | (4) | (8) | (7) | (6) | (6) | (4) | (2) | (1) | 0 |
Net Debt
|
|||
| 3 | 4 | 8 | 7 | 4 | 5 | 4 | 2 | 5 | 0 |
Sh' Equity
|
|||
| (61.03%) | (16.27%) | 39.39% | (17.06%) | (43.08%) | 6.63% | (24.95%) | (53.90%) | (18.71%) | (159.91%) |
ROA
|
|||
| (630.17%) | (2,433.59%) | (247.81%) | (208.83%) | 0.00% | 0.00% | (197.84%) | (223.42%) | (10.93%) | 0.00% |
ROIC
|
|||
| (67.20%) | (24.77%) | 50.01% | (17.61%) | (55.78%) | 9.73% | (28.89%) | (57.31%) | (26.83%) | (269.02%) |
ROE
|
|||
XTL Biopharmaceuticals Ltd. (XTLB) key facts
- XTL Biopharmaceuticals Ltd. (XTLB) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of September 25, 2026, XTLB traded at $2.20, a market capitalization of $9.7 million.
- Return on equity was −269.0% and debt-to-equity -1.83.
XTL Biopharmaceuticals Ltd. (XTLB) Latest News
30 Jun
XTL Biopharmaceuticals Ltd. completed the acquisition of Psyga Bio Ltd. Acquisition of Psyga Bio marks major strategic expansion for XTL Biopharmaceuticals operations and portfolio.
22 May
XTL Biopharmaceuticals Ltd. received a Nasdaq staff determination to delist its securities for non-compliance with listing requirements. Nasdaq delisting determination threatens to push XTLB shares to over-the-counter markets with reduced visibility and liquidity.
29 Apr
XTL Biopharmaceuticals Ltd. (XTLB) to acquire Psyga Bio, establishing a leading psychedelic biotechnology platform featuring an advanced clinical pipeline, licensed GMP manufacturing, and proprietary psilocybin technologies. Acquisition transforms XTLB into a psychedelic biotech leader with clinical pipeline, GMP manufacturing, and proprietary psilocybin tech, redefining its competitive position.
27 Feb
XTL Biopharmaceuticals Ltd. (XTLB) received a staff delist determination from Nasdaq and plans to request a hearing. Nasdaq delist determination threatens exchange listing status, significantly harming liquidity, visibility, and investor sentiment.
29 Jan
XTL Biopharmaceuticals Ltd. (XTLB) provided an update on its recent developments, highlighting progress in its clinical programs and strategic initiatives. The company is advancing its lead product candidate, which targets specific medical conditions, and is actively engaging with regulatory bodies to facilitate its development. Additionally, XTLB is exploring partnerships to enhance its market position and accelerate growth. Financial updates indicate a stable cash position, supporting ongoing research and operational activities. Recent developments may moderately influence XTLB's financial performance and competitive positioning in the biopharmaceutical market.
23 Jan
XTL Biopharmaceuticals Ltd. (XTLB) has received a notification from Nasdaq regarding a deficiency in its minimum stockholders' equity requirement. The company is currently working to address this issue and is exploring options to regain compliance with Nasdaq's listing standards. XTLB's management is committed to taking necessary actions to ensure the company's continued listing on the exchange. The notification indicates a compliance issue that could affect investor sentiment and operational focus.
13 Jan
XTL Biopharmaceuticals Ltd. has acquired an 85% stake in NeuroNOS, positioning itself to enter the autism market. The acquisition is backed by Nobel Prize-winning scientific leadership, which may enhance the company's research and development capabilities in this significant therapeutic area. Acquiring a majority stake in a company focused on autism, a large and growing market, is a strategic move that could significantly impact XTLB's future performance.
XTL Biopharmaceuticals Ltd. has acquired 85% of Beyond Air’s subsidiary NeuroNOS, marking its entry into the autism market. The acquisition is backed by Nobel Prize-winning scientific leadership, positioning XTLB to leverage innovative approaches in addressing autism-related challenges. The acquisition of NeuroNOS represents a significant strategic move into a large market with potential for impactful product development.
XTL Biopharmaceuticals Ltd. (XTLB) has been identified as one of the top midday gainers in the stock market, reflecting a positive shift in investor sentiment and market performance for the company. This uptick in stock value may be attributed to recent developments or announcements that have resonated well with investors, indicating a potential for growth and increased interest in XTLB's future prospects. The stock's midday gain suggests a moderately noticeable influence on market sentiment and potential financial performance.
7 Apr
XTL Biopharmaceuticals Ltd. has appointed Mr. Noam Band as its new Chief Executive Officer. Band brings extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. His appointment is expected to drive the company's strategic initiatives and enhance its operational capabilities as it continues to develop its product pipeline. The appointment of a new CEO may influence the company's strategic direction and operational effectiveness.
14 Aug
XTL Biopharmaceuticals Ltd. acquired The Social Proxy, an AI web data company, and completed a private placement of $1.5 million to support the growth of the newly acquired subsidiary. The acquisition of The Social Proxy and the private placement of $1.5 million are significant strategic moves that are expected to alter the company's trajectory and enhance its competitive position.
5 Jun
XTL Biopharmaceuticals Ltd. acquired The Social Proxy, an AI web data company, in a definitive share purchase agreement. Acquisition of The Social Proxy is a significant move that expands XTLB's IP portfolio and has the potential to impact its future growth and market performance.
20 Mar
XTL Biopharmaceuticals Ltd. acquires The Social Proxy, a web data AI company, in a transaction involving private placement of $1.5 million. The acquisition of The Social Proxy is a significant move that expands XTLB's IP portfolio and has the potential to impact its future growth and market performance.
20 Oct
XTL Biopharmaceuticals received Nasdaq notification for minimum bid price deficiency. Notification may moderately influence financial performance and market sentiment.